2019 ÇÏ°è ºÐÀÚÆó¾Ï¿¬±¸È¸ Àӻ󿬱¸ ¿öÅ©¼ó : 2019-08-31±³À°ÀÏÀÚ : 2019-08-31
±³À°Àå¼Ò : ¹é¹ü ±è±¸ ±â³ä°ü ÄÁº¥¼ÇȦ
±³À°ÁÖÁ¦ :
2019 ÇÏ°è ºÐÀÚÆó¾Ï¿¬±¸È¸ Àӻ󿬱¸ ¿öÅ©¼óÁÖÃÖ±â°ü : ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÐÀÚÆó¾Ï¿¬±¸È¸
´ã´çÀÚ : Á¤Çý¼±
¿¬¶ôó : 02-575-3825
À̸ÞÀÏ :
katrd@hanmail.net ±³À°Á¾·ù : ³»°úÀÇÇб³À°
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 20,000¿ø
ºñ°í »çÀüµî·Ï : 10,000¿ø ÇöÀåµî·Ï : 20,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-31 ¹é¹ü ±è±¸ ±â³ä°ü ÄÁº¥¼ÇȦ 13:00~14:00 ÅؽºÆ® ¸¶ÀÌ´× ±â¹Ý ÁøÂû±â·Ï ºÐ¼® ¼Û¹Î(¿¬¼¼´ëÇб³ ¹®°ú´ëÇÐ ¹®ÇåÁ¤º¸Çаú)
±³À°½Ã°£ 08-31 ¹é¹ü ±è±¸ ±â³ä°ü ÄÁº¥¼ÇȦ 14:40~15:00 Afatinib RWE Cohort from Multi-center Setting À̽·æ(°í·ÁÀÇ´ë ³»°ú)
±³À°½Ã°£ 08-31 ¹é¹ü ±è±¸ ±â³ä°ü ÄÁº¥¼ÇȦ 15:00~15:20 Real World Outcome of Crizotinib for Positive ALK Mutation ±è¿¬ÁÖ(¿ï»êÀÇ´ë ³»°ú)
±³À°½Ã°£ 08-31 ¹é¹ü ±è±¸ ±â³ä°ü ÄÁº¥¼ÇȦ 15:20~15:40 The Role of eCRF, DM in the Cohort Study ÀÌ°æ½Å(ÇÁ·ÎÅ¥¶óƼ¿À)
Åä·Ð 08-31 ¹é¹ü ±è±¸ ±â³ä°ü ÄÁº¥¼ÇȦ 15:40~15:50 Åä·Ð ()
±³À°½Ã°£ 08-31 ¹é¹ü ±è±¸ ±â³ä°ü ÄÁº¥¼ÇȦ 16:10~16:30 ºÐ»êÇü ´Ù±â°ü Æó¾Ï ÄÚȣƮ ±¸Ãà »ç¾÷ ¼Ò°³ ÃÖâ¹Î(¿ï»êÀÇ´ë ³»°ú)
±³À°½Ã°£ 08-31 ¹é¹ü ±è±¸ ±â³ä°ü ÄÁº¥¼ÇȦ 16:30~16:50 Æó¾Ï ´ÙÇÐÁ¦ ÄÚȣƮ ±¸Ãà °æÇè »ç·Ê ¹Úö±Ô(Àü³²ÀÇ´ë ³»°ú)
Åä·Ð 08-31 ¹é¹ü ±è±¸ ±â³ä°ü ÄÁº¥¼ÇȦ 16:50~17:10 Åä·Ð ()